Ethylene

Ethylene

SCHEMBL710068

C=C.CC(S(=O)(=O)O)S(=O)(=O)O

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.33
CA5B Q9Y2D0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27433721 0.93 CA5A (0.39) CA5ACA5B
SCHEMBL23269 0.93 CA5A (0.39) CA5ACA5B
Ammonia Solution, Strong SCHEMBL5760496 0.89 CA5A (0.36) CA5ACA5B
Water SCHEMBL384922 0.89 CA5A (0.36) CA5ACA5B
SCHEMBL17510158 0.89 CA5A (0.36) CA5ACA5B
SCHEMBL2571875 0.89 CA5A (0.36) CA5ACA5B
SCHEMBL14974666 0.89 CA5A (0.36) CA5ACA5B
SCHEMBL16756653 0.89 CA5A (0.36) CA5ACA5B
Water SCHEMBL1614964 0.89 CA5A (0.36) CA5ACA5B
SCHEMBL29170918 0.89 CA5A (0.36) CA5ACA5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114144407-B Process for producing cyclic disulfonate compound 住友精化株式会社 2024-02-13 CN disclosed
US-11742523-B2 Electrolyte solutions ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2023-08-29 US disclosed
CN-114144407-A Process for producing cyclic disulfonate compound 住友精化株式会社 2022-03-04 CN disclosed
US-20210242503-A1 ELECTROLYTE SOLUTIONS ASCEND PERFORMANCE MATERIALS OPERATIONS LLC (US) 2021-08-05 US disclosed
EP-2067770-B1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER WAKO PURE CHEM IND LTD (JP) 2017-04-12 EP disclosed
US-9583789-B2 Non-aqueous electrolyte secondary battery NEC CORPORATION (JP) 2017-02-28 US disclosed
EP-2615682-B1 ENERGY STORAGE ELEMENT, METHOD OF PRODUCING ENERGY STORAGE ELEMENT, AND NON-AQUEOUS ELECTROLYTE GS YUASA INT LTD (JP) 2016-10-19 EP disclosed
US-20150155597-A1 NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY NEC CORPORATION (JP) 2015-06-04 US disclosed
US-8986881-B2 Energy storage element, method of producing energy storage element, and non-aqueous electrolyte GS YUASA INTERNATIONAL LTD. (JP) 2015-03-24 US disclosed
US-20130183580-A1 ENERGY STORAGE ELEMENT, METHOD OF PRODUCING ENERGY STORAGE ELEMENT, AND NON-AQUEOUS ELECTROLYTE GS YUASA INTERNATIONAL LTD. (JP) 2013-07-18 US disclosed
US-8269038-B2 Process for production of sulfonic acid ester WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-09-18 US disclosed
US-8124793-B2 Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents CRONYN MARSHALL W (US) 2012-02-28 US disclosed
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-02-18 US disclosed
US-20090176805-A1 DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS CRONYN MARSHALL W 2009-07-09 US disclosed
EP-2067770-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER Wako Pure Chemical Industries, Ltd. (JP) 2009-06-10 EP disclosed
US-4950768-A ANTICARCINOGENIC AGENTS CRONYN MARSHALL W (US) 1990-08-21 US disclosed
EP-0168478-B1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES CRONYN, Marshall W. (US) 1989-04-05 EP disclosed
EP-0168478-A4 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES. CRONYN MARSHALL W 1986-11-07 EP disclosed
EP-0168478-A1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES. CRONYN MARSHALL W 1986-01-22 EP disclosed
WO-1985003075-A1 CANCER CHEMOTHERAPEUTIC CYCLIC AND ACYCLIC DISULFONIC ESTER COMPOUNDS, METHOD OF USE THEREFOR, AND INTERMEDIATES CRONYN MARSHALL W 1985-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041916-A1 PROCESS FOR PRODUCTION OF SULFONIC ACID ESTER SULT1A1, SULT2A1, STS CA5A 1103/4885CA5B 1460/4885
US-20090176805-A1 DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS MGMT, ETV6, EI24 CA5A 975/4885CA5B 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.